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BSTRACT
 
Therapy with inhaled corticosteroids (ICS) has been
regarded as first-line treatment for persistent asthma
because of its highly potent anti-inflammatory effects.
However, the limitations of such therapy are also well
known. Although the anti-inflammatory effects of ICS
are initially dose dependent, a plateau of response is
reached at medium doses and a further increase of the
dose is not associated with any significant additional
therapeutic benefit. In contrast, it has been reported
that a proportion of patients with severe asthma may
benefit from prolonged treatment with higher doses of
ICS in terms of a reduction in the frequency of severe
acute exacerbations. Inhaled corticosteroids also exhibit
a dose–response relationship for systemic adverse
effects, which are most pronounced in patients receiv-
ing high doses of ICS. Thus, the long-term systemic
burden of steroids should be minimized by always
attempting to reduce the dose of ICS to the minimum
required to maintain acceptable control of asthma
symptoms and instituting, where required, add-on
therapy with other controller agents, such as inhaled
long-acting 
 
β
 
2
 
-adrenergic receptor agonists and leuko-
triene receptor antagonists.
 
Key words:
 
add-on effect, bronchial asthma, dose–
response relationship, inhaled corticosteroids, long-
acting 
 
β
 
2
 
-adrenergic receptor agonist.
 
I
 
NTRODUCTION
 
The therapeutic strategy against chronic asthma has
evolved over the past 30 years, since the first introduc-
tion of inhaled corticosteroids (ICS) for asthma control,
in accordance with the evolution in the understanding
of the basic concepts concerning the development of
asthma and the progress of investigations related to the
pathogenesis of asthma (i.e. of the mechanisms under-
lying airway inflammation and remodeling; Fig. 1). The
beneficial effects of anti-inflammatory therapy with ICS
in cases of chronic asthma have been particularly well
documented and several national and international
asthma management guidelines recommend the use of
ICS as first-line therapy for all except the mildest cases
of asthma (i.e. mild intermittent asthma).
 
1,2
 
 The Japanese
guidelines recommend the earlier introduction of ICS for
even cases of mild intermittent asthma.
 
3
 
 Recent epidemi-
ological studies have demonstrated that ICS therapy can
prevent major asthma outcomes, such as visits to the
emergency room, hospitalization and near-fatal attacks,
and that, as reported from several countries including
Japan, the treatment is associated with a reduction of
asthma mortality.
 
4
 
 The asthma management guidelines
recommend adoption of a step-wise approach to ther-
apy, with either increases or decreases in the dose of ICS
according to the clinical situation, and add-on therapy
with other controller agents, such as long-acting
 
β
 
2
 
-adrenergic receptor agonists (LABA), leukotriene
receptor antagonists (LTRA) and theophylline, if disease
control is inadequate with the recommended doses of
ICS. It has been suggested that the clinical decision
regarding whether to increase the dose of ICS or institute
add-on therapy with other controller agents in cases not
responding satisfactorily to low- or medium-dose steroids
should be made rationally, taking into consideration two
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factors: (i) the dose–response relationship for ICS; and
(ii) the benefits of add-on therapy with other controller
agents, especially LABA, in comparison with those of a
further increase in the dose of ICS. In the present review,
these two clinically important considerations in the
management of persistent asthma are discussed.
DOSE–RESPONSE RELATIONSHIP FOR ICS
As stated in the Global Initiative for Asthma (GINA)1 and
the Expert Panel Report (EPR),2 almost all the guidelines
for the management of asthma suggest determining the
dose of ICS to be prescribed to asthma patients on
the basis of the level of severity of the asthma symptoms.
In GINA 2002,1 for example, the doses of beclometha-
sone dipropionate (BDP) recommended are as follows:
low dose (less than 500 µg/day) for step 2 (mild persist-
ent asthma); low to medium dose (200–1000 µg/day)
for step 3 (moderate persistent asthma); and high dose
(>1000 µg/day) for step 4 (severe persistent asthma),
although a precise guideline for increasing the dose of
ICS within the same step of asthma severity is not specified
(Table 1). In contrast, the EPR update2 contends that
increasing the dose of ICS from low to medium doses is
as effective as the addition of an LABA to low-dose ICS
for moderate persistent asthma and suggests that the
clinician could choose either option for the treatment of
moderate persistent asthma. In choosing one of the two
options, clinicians may rely on either their own clinical
experience or on evidence from clinical trials. In this
context, although personal experience or preference
may play a role in the decision-making process, results
obtained from good clinical studies should be considered
as a priority. Now, the dose-dependent anti-inflammatory
effects of different ICS preparations currently available
are described.
In the case of BDP, the classic ICS, the limitation
posed by the dose–response relationship was already
recognized when the drug was first developed.5 Although
early research dating back to 1979 demonstrated that
there was no significant difference in the oral steroid-
sparing effect between low-dose (400 
 
µ
 
g) and medium-
dose (800 µg) BDP,6 recent studies investigating the
dose–response relationship of ICS revealed that the
anti-inflammatory effects of this drug increased in a dose-
dependent manner from low to medium doses and that
Fig. 1 The transition of therapeutic strategy for chronic asthma. ICS, inhaled corticosteroids; SABA, short-acting β2-adrenergic
receptor agonist.
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no significant additional therapeutic benefit could be
obtained with further increases in the dose of the ICS to
the high-dose range of BDP.
 
7–9
 
 A recent Cochrane review
reported that BDP exhibits a shallow dose–response
curve for several outcome measures (morning peak
expiratory flow rate (PEF), forced expiratory volume in 1 s
(FEV
 
1.0
 
), histamine-induced bronchial hyperresponsive-
ness) over a dose range of 400–1600 
 
µ
 
g/day.
 
10
 
Such a dose–response relationship for asthma outcome
can also be observed for budesonide (BUD) and flutica-
sone propionate (FP), which has recently become a
widely prescribed ICS in the treatment of persistent asthma.
Busse 
 
et al
 
.
 
11
 
 reported that administration of BUD via Turbu-
haler was associated with a consistent dose-dependent
improvement of all the parameters measured, including
morning PEF, FEV
 
1.0
 
, asthma symptom scores and rescue
bronchodilator use, when the highest dose (1600 
 
µ
 
g/day)
was compared with the lowest dose (200 
 
µ
 
g/day) among
subjects with mild to moderate asthma. However, no sig-
nificant difference was observed between medium-dose
(400–800 
 
µ
 
g/day) and highest-dose BUD.
 
11
 
 Although
McFadden 
 
et al.
 
12
 
 reported the absence of any significant
differences in lung function parameters (FEV
 
1.0
 
 and
morning PEF) between patients receiving low-dose BUD
(200 
 
µ
 
g/day administered once daily) and medium-dose
BUD (400 
 
µ
 
g/day once daily), numerous studies have
indicated a reasonable dose–response relationship between
low-dose and medium-dose BUD among patients with
stable mild to moderate asthma.
 
13–15
 
Fluticasone propionate had the most potent anti-
inflammatory effect among all the ICS currently available.
A compilation of the reported 
 
in vivo
 
 and 
 
in vitro
 
 meas-
ures of the functional activities of the available ICS agents
suggested the following relative potencies FP > BUD
= BDP > triamcinolone acetonide and the relative
potency ratio for these inhalational steroids was 1 : 2 :
2–4 : 8, respectively, with FP (with a value of 1) being
considered as the most potent.
 
16
 
 Even this most-potent
ICS was reported to show a plateau in its dose–response
curve for anti-inflammatory effects.
 
17–20
 
 Since the appear-
ance of the first report by Dahl 
 
et al
 
.
 
17
 
 that suggested a
dose-dependent improvement of asthma control in
patients with moderate asthma (morning PEF, FEV
 
1.0
 
, per-
centage of symptom-free days and rescue bronchodilator
use) with the administration of FP in the dose range
100 
 
µ
 
g/day (low dose) to 800 
 
µ
 
g/day (high dose), almost
all the reports discussing the dose–response relationship
for FP have demonstrated that a significant dose–response
relationship exists for the dose range between low doses
(100–250 
 
µ
 
g) and medium doses (250–500
 
µ
 
g) and that
the effect of FP gradually plateaus at higher doses (greater
than 500 
 
µ
 
g/day).
 
18–20
 
 Similar results have been reported
for the other ICS available currently, such as triamcinolone
acetonide
 
21
 
 and mometasone furoate.
 
22
 
We have reviewed the dose–response relationship of
each of the currently available ICS agents and believe
that some difficulties still exist in the interpretation of the
results. Demonstration of the dose–response relationship
of ICS may be dependent on a number of factors, includ-
ing the severity of the disease, the treatment received
before entry into the study, treatment duration and the
primary outcome measures. Objective measures, such as
morning PEF and FEV
 
1.0
 
, may be the most relevant for the
assessment of the efficacy of ICS, because not only could
the definitions of symptoms and exacerbations vary
among studies, but also a long study duration may be
necessary to assess the improvement in bronchial hyper-
responsiveness and the systemic steroid-sparing effect of
ICS. Studies adopting these objective measurements as
the primary end-points tend to reveal a more consistent
dose–response relationship than those using other varia-
bles. Moreover, if the study includes patients with more
severe grades of asthma, the likelihood of demonstrating
a dose–response relationship increases.
 
23
 
 However, a
major meta-analysis of studies conducted on the
dose–response relationship of ICS still concluded that a
dose–response relationship was evident from the low to
the medium end of the recommended dose range (and
was not driven disproportionately by the high-dose
groups) and that increasing the dose of ICS to the high-
dose range did not appear to increase the efficacy of ICS
in patients with mild to moderate persistent asthma.
 
24,25
 
Table 1
 
Estimated equipotent doses of inhaled corticosteroid (from GINA 2002
 
1
 
)
Low dose Medium dose High dose
Beclomethasone 200–500 
 
µ
 
g/day 500–1000 
 
µ
 
g/day > 1000 
 
µ
 
g/day
Budesonide 200–400 
 
µ
 
g/day 400–800 
 
µ
 
g/day > 800 
 
µ
 
g/day
Fluticasone 100–250 
 
µ
 
g/day 250–500 
 
µ
 
g/day > 500 
 
µ
 
g/day
Triamcinolone acetonide 400–1000 
 
µ
 
g/day 1000–2000 
 
µ
 
g/day > 2000 
 
µ
 
g/day
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S
 
YSTEMIC
 
 
 
ADVERSE
 
 
 
EFFECTS
 
 
 
OF
 
 ICS
 
When a drug is assessed for clinical use, it is important
to evaluate both its efficacy and safety. We first reviewed
the efficacy of ICS and shall now consider the dose-
dependency of the adverse effects of ICS. Inhaled
corticosteroids were developed to provide the beneficial
therapeutic effects of corticosteroids while minimizing
the potential for the known adverse consequences of
chronic oral steroid use. In general, the systemic effects
of ICS are exerted by that portion of the drug that is
swallowed and absorbed through the gastrointestinal
tract and not by the portion that is eliminated by first-
pass metabolism or delivered to the lung and absorbed.
If administered in high enough doses, any of the
currently available ICS could be associated with clini-
cally significant systemic activity. In numerous review
articles on the systemic adverse effects of ICS, the effects
of ICS on the hypothalamic–pituitary–adrenal (HPA) axis,
growth in children, bone mineral density, especially in
menopausal women, skin and eyes have been evaluated
in detail.
 
23,25–29
 
The standard method for assessing the systemic activ-
ity of steroids in short-term studies is measurement of HPA
axis function, whereas other adverse effects can develop
only with prolonged use of the drug. Inhaled cortico-
steroids, even in the medium dose range, can produce
measurable effects on the HPA axis; however, clinically
significant adrenal suppression, such as acute adrenal
crisis, is unlikely to occur except at extraordinarily high
doses.
 
30
 
 Furthermore, no long-term cumulative effects on
the HPA axis have been detected in either children or
adults receiving low to medium doses of ICS.
The effect of ICS on the growth in children can also be
seen even at low to medium doses. A decrease in the
growth velocity that would be expected to produce a
0.5–1.5 cm difference in height could take place after
the first 1 year of treatment in children receiving ICS.
Data are still insufficient to determine whether the
approximate 1 cm loss of height in children during
the first year of steroid treatment could eventually result
in failure of the children to attain their predicted adult
height. However, the results of the longest controlled
prospective trial to date, in which patients were treated
with ICS from 4 to 6 years of age, may be reassuring.
 
31
 
That study reported that the reduction in growth velocity
associated with the administration of 400 
 
µ
 
g BUD
occurred during the first year of therapy and that, subse-
quently, the growth velocity was similar in all treatment
groups. Thus, the cumulative reduction of growth was
less than 1 cm. Current review articles suggest that
controlling asthmatic disease activity in children would
usually outweigh the disadvantages of any potential sys-
temic adverse bioactivity of ICS in relation to long-term
growth, although there is still inadequate evidence to
determine whether continuous administration of ICS
throughout childhood would affect attainment of the final
predicted adult height.
 
27,32
 
Inhaled corticosteroids affect bone mineral density,
increasing the risk of osteoporosis and fractures in a
dose-dependent fashion; the risk appears to be espe-
cially significant at high doses. The possibility of posterior
subcapsular cataracts or open-angle glaucoma should
also be borne in mind in patients receiving prolonged
(more than 3 months) high-dose ICS therapy. According
to the results of meta-analyses of studies on the major
side-effects of ICS, a dose–response relationship was
evident for the systemic adverse effects of ICS and,
furthermore, these undesirable effects were most pro-
nounced among patients receiving high-dose ICS. Thus,
it would seem prudent to perform regular annual or
biennial check-ups to monitor for the systemic adverse
effects of ICS, particularly in the small proportion of
patients dependent on prolonged high-dose ICS therapy.
Taking account of these results reported from numer-
ous studies and meta-analyses, the dose–response char-
acteristics of ICS for both anti-inflammatory activity and
systemic activity could best be expressed as log-linear
curves
 
29,33,34
 
 (Fig. 2). It may take a fourfold increase of
the dose to produce a 50% increase in effect, explained
 
Fig. 2
 
Dose–response curves for the efficacy and toxicity of an
inhaled corticosteroids (ICS). The two vertical lines indicate how
the therapeutic index for any ICS narrows as the dose increases.
(Modified from Kelly.
 
29
 
)
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by the relatively flat nature of the dose–response curves
for ICS. As seen in Fig. 2, with an increase in the dose of
any ICS, the therapeutic index (i.e. the ratio of the thera-
peutic effect to systemic adverse effect) decreases. Thus, it
is rather difficult to gain a favorable therapeutic index
when using high doses of ICS for the control of asthma.
These are the reasons why the guidelines recommend
that the long-term systemic burden of steroids should be
minimized by always attempting to reduce the mainte-
nance dose of ICS to the minimum necessary for optimal
asthma control and for a reasonable quality of life.
Considering the balance between the anti-inflammatory
effects and systemic adverse effects of ICS, treatment with
high doses of ICS could be regarded as not being benefi-
cial at all in the clinical setting. Nevertheless, every guide-
line still recommends the use of high-dose ICS for the
treatment of patients with severe persistent asthma. This
recommendation stems from another aspect of high-dose
ICS treatment, namely its ability to prevent severe acute
exacerbations of asthma in patients with severe asthma.
Pauwels 
 
et al
 
.
 
35
 
 conducted a double-blind, randomized
study in four treatment groups to evaluate the effects of
the addition of inhaled formoterol (an LABA) to both
low-dose and high-dose BUD. The four treatment groups
received 200 
 
µ
 
g/day (low-dose) BUD with or without
formoterol, or 800 
 
µ
 
g/day (high-dose) BUD with or
without formoterol.
 
35
 
 In this Formoterol and Cortico-
steroids Establishing Therapy (FACET) study, symptoms of
asthma and lung function parameters, such as FEV
 
1.0
 
 and
morning PEF, improved with both the addition of formot-
erol and increasing the dose of inhaled BUD, but the
improvement was significantly greater with the addition of
formoterol. The addition of formoterol also decreased
the incidence of both severe and mild exacerbations,
independent of the dose of BUD. In contrast, the rates of
severe and mild exacerbations were lower among the
patients given higher doses of BUD, independent of
the addition of formoterol. Only in patients with severe
exacerbations were the effects of increasing the dose
of BUD significantly more pronounced than the effects of
the addition of formoterol. These results suggest that
increasing the maintenance dose of ICS may be a more
appropriate therapeutic step in patients with repeated
severe exacerbations of asthma. This study provides the
rationale for the administration of high-dose ICS to
patients with severe persistent asthma.
 
35
 
Finally, GINA 2002
 
1
 
 summed up as follows: because
the dose–response curve for ICS is relatively flat for a
number of outcome measures in asthma (e.g. symptoms,
lung function measurements and airway hyperrespon-
siveness), increasing the dose of ICS to the high-dose
range provides little further additional benefit in terms of
asthma control, whereas it increases the risk of adverse
effects. Thus, add-on therapy with another class of con-
troller should be preferred over increasing the dose of
ICS. Nonetheless, it must be stated here that there is a
clear relationship between the administration of high-
dose ICS and a reduction in the frequency of severe acute
exacerbations of asthma in patients with severe asthma.
Therefore, some patients with severe asthma may benefit
from prolonged treatment with high doses of ICS, which
also allows a decrease or withdrawal of the oral cortico-
steroid dose in these patients.
 
A
 
DD
 
-
 
ON
 
 
 
EFFECT OF LABA
Now, we move to the other issue of the add-on effect
of other long-term control agents in the treatment of
asthma with ICS. Ever since the early 1990s, when the
dose dependence of the anti-inflammatory effects of ICS
was first demonstrated, numerous studies investigating
the effects of the addition of other controller agents to
ICS on asthma control have been conducted. Among
these, studies comparing the effects of addition of
inhaled LABA (salmeterol and formoterol) with the effects
of increasing the dose of ICS have been the most
noteworthy, starting from the report by Greening et al. in
1994.36 In that study, comparing PEF as a primary
variable between a group administered 400 µg/day
BDP plus 100 µg/day salmeterol and a group adminis-
tered maintenance therapy with only 1000 µg/day BDP
for 6 months in mild to moderate asthma, significantly
more favorable effects were observed in the group
receiving add-on therapy with salmeterol, not only in
terms of the change of PEF from the baseline, but also in
terms of the need for rescue medication being reduced
significantly and the number of symptom-free days
increasing. An excellent meta-analysis37 of nine random-
ized, double-blind clinical studies36,38–45 that compared
the efficacy of the addition of salmeterol with that of
increasing the dose of ICS (doubling of the dose)
revealed favorable efficacy of the add-on therapy with
salmeterol. This review article37 concluded that the
addition of salmeterol to low or moderate doses of ICS
resulted in improved lung function parameters, an
increase in the number of days and nights without
symptoms and a reduction in the use of rescue medi-
cation, namely short-acting β2-adrenergic receptor
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agonists, with no increase in the occurrence of exacer-
bations of any severity. Furthermore, recent studies
reported not only the suppressive effect of LABA on
airway remodeling,46 but also the steroid-sparing effect
of LABA in patients with stable mild to moderate asthma
receiving medium-dose ICS.47 With the accumulation of
such evidence, combined therapy with an LABA and a
maintenance dose of ICS has already acquired an
established role in the control of mild to moderate
chronic asthma. GINA 2002 states that the addition of
an LABA should be considered before increasing the
dose of ICS, when standard introductory doses of ICS
fail to control the asthma.1
The long-term addition of LABA to ICS has already
proved to be relatively safe. Administration of an inhaled
LABA is associated with fewer adverse effects, such as
cardiovascular stimulation, muscle tremor and hypo-
kalemia, than administration of an oral β2-adrenergic
receptor agonist. Although a potential masking effect of
LABA on airway inflammation was reported during rapid
reduction of the dose of ICS among patients with moder-
ate asthma,48 long-term treatment with LABA did not
appear to influence the persistent inflammatory changes
observed in asthma when the drug was combined with an
appropriate dose of ICS.35,49
ADD-ON EFFECT OF OTHER CONTROLLER 
AGENTS
Another addition to the choice of anti-inflammatory
agents for persistent asthma is the LTRA. These drugs
work by inhibiting cysteinyl leukotrienes involved in the
inflammatory process, which have been shown to be
unaffected by steroids. In addition to these uniquely
advantageous anti-inflammatory characteristics, compli-
ance may also be improved with LTRA combination
therapy, because compliance with inhaled medications
is generally lower than that seen with oral medications.
In spite of these advantages, add-on therapy with LTRA
has not been shown to be as effective as that with
LABA,50 even though there is evidence that LTRA used as
add-on therapy could have a steroid-sparing effect in
patients with moderate to severe asthma51 and may
improve asthma control in patients whose asthma
cannot be controlled even with high doses of ICS.52
Only a few direct comparisons have been made
between add-on therapy with LABA and that with LTRA.
Two short-term (12 weeks) studies concluded that
symptomatic patients on low-dose ICS therapy showed
significantly greater improvement in asthma control
when add-on therapy with LABA was initiated compared
with add-on therapy with LTRA.53,54 However, a recent
long-term (1 year) study reported that treatment with
montelukast and FP was not inferior to that with sal-
meterol and FP, using asthma exacerbations and asthma-
specific quality of life as the main outcome measures,
although the improvements in lung function parameters
were more favorable in cases receiving salmeterol
with FP.55 These findings suggest that add-on therapy
with LTRA could provide equivalent clinical control to
add-on therapy with LABA. Despite some problems with
LTRA, such as that an estimated 40–50% of asthmatics
can be classified as non-responders to these drugs, the
position of add-on therapy with LTRA could change
among patients with persistent asthma in the near
future.
Theophylline, a methylxanthine, is another potential
choice for combination therapy with ICS. Theophylline
has been used for over 60 years and remains one of the
most widely prescribed drugs for the treatment of airway
diseases worldwide. However, in many industrialized
countries, theophylline has recently become a third-line
treatment drug, for use only in some poorly controlled
patients, because of the critical disadvantage of the
narrow therapeutic index of this drug. A meta-analysis of
studies comparing the safety and efficacy of theophylline
versus LABA revealed that LABA have a superior effect
profile to theophylline in terms of lung function para-
meters and number of symptom-free nights.56 Although
recent studies have reported novel mechanisms of the
anti-inflammatory actions of theophylline, namely that it
activates histone deacetylase, which suppresses the
expression of inflammatory genes, the position of theo-
phylline as a third-line controller is unlikely to change for
at least a decade.
In conclusion, the anti-inflammatory effects of ICS
reach a plateau at medium doses; further increases of the
dose are not associated with any significant additional
therapeutic benefit, except that a proportion of patients
with severe asthma have been reported to benefit from
prolonged treatment with higher doses of ICS in that the
frequency of severe exacerbations was reduced in these
patients. However, the dose–response relationship of ICS
for systemic adverse effects was evident throughout the
entire dose range and these effects were most pro-
nounced in patients receiving high-dose ICS. Thus, the
long-term systemic burden of steroids should be mini-
mized by always attempting to reduce the dose of ICS to
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the minimum required to maintain acceptable control of
asthma symptoms and instituting, where required, add-
on therapy with either LABA or LTRA.
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